22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › CYTOKINETICS INC. › 2024-2025

CYTOKINETICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and CYTOKINETICS INC.’s Form 8-K, filed May 16, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Ballot items
  • 352Asset managers, any item
  • 3,391Fund votes
  • May 14, 2025Meeting date

Results at a glance

Meeting of May 14, 2025: 7 items on CYTOKINETICS INC.’s Form 8-K, filed May 16, 2025: 4 approved · 3 passed (calculated).

Dissent

Notable dissent: 2 directors (14.5%, 12.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CYTOKINETICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by CYTOKINETICS INC.

These tallies are CYTOKINETICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 16, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CYTOKINETICS INC. — official shareholder meeting results, meeting held May 14, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: John T. Henderson 86,834,097---- 14,784,9438,867,164 85%Passed (calculated)—
Elect Director: B. Lynne Parshall 98,261,990---- 3,357,0508,867,164 97%Passed (calculated)—
Elect Director: Muna Bhanji 89,316,977---- 12,302,0638,867,164 88%Passed (calculated)—
2. Approval of the Amendment and Restatement of the Amended and Restated 2004 Equity Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under Amended and Restated 2004 Equity Incentive Plan by 5,000,000 shares of common stock 97,782,7713,668,240168,029 --8,867,164 96%Approved—
3. Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock available for issuance by the Company from 163,000,000 to 326,000,000 shares of common stock 107,322,0803,009,572154,552 --0 97%Approved—
4. Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025 110,254,21677,441154,547 --0 99.9%Approved—
5. Advisory Vote on Executive Compensation 96,760,2724,607,831250,937 --8,867,164 95%Approved—

Source: CYTOKINETICS INC., Form 8-K, filed with the SEC on May 16, 2025 — read the filing on EDGAR.

How asset managers voted at the CYTOKINETICS INC. 2024-2025 meeting

352 asset managers disclosed a vote on at least one CYTOKINETICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: B. Lynne Parshall

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 98,261,990WITHHELD: 3,357,050
Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: B. Lynne Parshall

CYTOKINETICS INC.’s own tally for this item (“Elect Director: B. Lynne Parshall”): 98,261,990 for, 3,357,050 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 102 asset managers voting on “To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard16,589,7500 00For
Fidelity10,803,4230 00For
BlackRock8,890,3540 00For
T. Rowe Price6,814,0550 00For
State Street1,639,9310 0103For
Charles Schwab1,301,1190 00For
Capital Group1,168,1100 00For
JPMorgan690,2880 00For
Columbia Threadneedle663,2810 00For
Jackson National606,6550 00For
Aberdeen602,4210 00For
Equitable226,8390 0330,121Mixed
AllianceBernstein00 0462,473Withhold
Principal330,6040 091,109Mixed
MUTUAL FUND SERIES TRUST382,0790 00For
HARBOR FUNDS360,8300 00For
Invesco315,6600 00For
Prudential/PGIM312,7440 00For
Goldman Sachs309,1150 00For
Brown Advisory Funds294,6680 00For
TIAA287,3270 00For
American Century283,5350 00For
MFS283,4950 00For
Hartford271,1350 00For
AB DISCOVERY GROWTH FUND, INC.00 0266,738Withhold

Fund voting reports, all 102 managers: 57,455,462 for, 1,195,206 withheld, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 2 asset managers voting on “To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RP Management, LLC980,3920 00For
Erste Asset Management GmbH60,4500 00For

Institutional-manager reports, all 2 managers: 1,040,842 for.

Elect Director: John T. Henderson

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 86,834,097WITHHELD: 14,784,943
Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: John T. Henderson

CYTOKINETICS INC.’s own tally for this item (“Elect Director: John T. Henderson”): 86,834,097 for, 14,784,943 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 102 asset managers voting on “To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard16,588,9070 0843For
Fidelity10,803,4230 00For
BlackRock8,890,3540 00For
T. Rowe Price1,481,6610 05,332,394Mixed
State Street1,639,9310 0103For
Charles Schwab1,301,1190 00For
Capital Group1,168,1100 00For
JPMorgan690,2880 00For
Columbia Threadneedle663,2810 00For
Jackson National225,0990 0381,556Mixed
Aberdeen00 0602,421Withhold
Equitable226,8390 0330,121Mixed
AllianceBernstein00 0462,473Withhold
Principal330,6040 091,109Mixed
MUTUAL FUND SERIES TRUST382,0790 00For
HARBOR FUNDS360,8300 00For
Invesco00 0315,660Withhold
Prudential/PGIM312,7440 00For
Goldman Sachs309,1150 00For
Brown Advisory Funds294,6680 00For
TIAA287,3270 00For
American Century283,5350 00For
MFS283,4950 00For
Hartford271,1350 00For
AB DISCOVERY GROWTH FUND, INC.00 0266,738Withhold

Fund voting reports, all 102 managers: 50,277,088 for, 8,373,580 withheld, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 2 asset managers voting on “To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RP Management, LLC980,3920 00For
Erste Asset Management GmbH60,4500 00For

Institutional-manager reports, all 2 managers: 1,040,842 for.

Elect Director: Muna Bhanji

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 89,316,977WITHHELD: 12,302,063
Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: Muna Bhanji

CYTOKINETICS INC.’s own tally for this item (“Elect Director: Muna Bhanji”): 89,316,977 for, 12,302,063 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 102 asset managers voting on “To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard16,589,7500 00For
Fidelity10,803,4230 00For
BlackRock8,890,3540 00For
T. Rowe Price1,481,6610 05,332,394Mixed
State Street1,640,0340 00For
Charles Schwab1,301,1190 00For
Capital Group1,168,1100 00For
JPMorgan690,2880 00For
Columbia Threadneedle663,2810 00For
Jackson National225,0990 0381,556Mixed
Aberdeen602,4210 00For
Equitable226,8390 0330,121Mixed
AllianceBernstein00 0462,473Withhold
Principal330,6040 091,109Mixed
MUTUAL FUND SERIES TRUST382,0790 00For
HARBOR FUNDS360,8300 00For
Invesco315,6600 00For
Prudential/PGIM312,7440 00For
Goldman Sachs309,1150 00For
Brown Advisory Funds294,6680 00For
TIAA287,3270 00For
American Century283,5350 00For
MFS283,4950 00For
Hartford271,1350 00For
AB DISCOVERY GROWTH FUND, INC.00 0266,738Withhold

Fund voting reports, all 102 managers: 51,404,373 for, 7,246,295 withheld, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 2 asset managers voting on “To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RP Management, LLC980,3920 00For
Erste Asset Management GmbH60,4500 00For

Institutional-manager reports, all 2 managers: 1,040,842 for.

Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of…

Official resultFund totals may overlapCAPITAL STRUCTUREReported outcome: Approved

97% Approved · of votes cast

FOR 97%
FOR: 107,322,080AGAINST: 3,009,572
Details: description as filed, official tally, votes by 100 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO CYTOKINETICS, INCORPORATED'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON AVAILABLE FOR ISSUANCE BY CYTOKINETICS, INCORPORATED FROM 163,000,000 TO 326,000,000 SHARES OF COMMON STOCK.

CYTOKINETICS INC.’s own tally for this item (“3. Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock available for issuance by the Company from 163,000,000 to 326,000”): 107,322,080 for, 3,009,572 against — passed, per its Form 8-K filed May 16, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock available for issuance by the Company from 163,000,000 to 326,000,000 shares of common stock.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 99 asset managers voting on “TO APPROVE AN AMENDMENT TO CYTOKINETICS, INCORPORATED'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO I” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard16,589,7500 00For
Fidelity10,803,4230 00For
BlackRock8,890,3540 00For
T. Rowe Price6,814,0550 00For
State Street1,639,98153 00For
Charles Schwab1,301,1190 00For
Capital Group1,168,1100 00For
JPMorgan690,2880 00For
Columbia Threadneedle663,2810 00For
Jackson National606,6550 00For
Aberdeen602,4210 00For
Equitable556,9600 00For
AllianceBernstein462,4730 00For
Principal421,7130 00For
MUTUAL FUND SERIES TRUST382,0790 00For
HARBOR FUNDS360,8300 00For
Invesco315,6600 00For
Prudential/PGIM308,1544,590 00For
Goldman Sachs309,1150 00For
Brown Advisory Funds294,6680 00For
TIAA287,3270 00For
American Century283,5350 00For
MFS283,4950 00For
Hartford271,1350 00For
AB DISCOVERY GROWTH FUND, INC.266,7380 00For

Fund voting reports, all 99 managers: 58,528,690 for, 56,996 against, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “TO APPROVE AN AMENDMENT TO CYTOKINETICS, INCORPORATED'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO I” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RP Management, LLC980,3920 00For

Institutional-manager reports, all 1 managers: 980,392 for.

Approval of the Amendment and Restatement of the Amended and Restated 2004 Equity Incentive Plan to: (i) increase the…

Official resultFund totals may overlapSHAREHOLDER RIGHTS AND DEFENSESReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 97,782,771AGAINST: 3,668,240
Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE CYTOKINETICS AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN TO: (I) INCREASE THE NUMBER OF AUTHORIZED SHARES RESERVED FOR ISSUANCE UNDER SUCH PLAN BY 5,000,000 SHARES OF COMMON STOCK AND (II) PROVIDE FOR LIMITATIONS ON THE MAXIMUM GRANT VALUE THAT NON-EXECUTIVE DIRECTORS MAY RECEIVE UNDER SUCH PLAN OF $1,000,000 FOR ANNUAL GRANTS TO CONTINUING DIRECTORS AND $1,250,000 FOR THE INITIAL GRANT TO NEW DIRECTORS.

CYTOKINETICS INC.’s own tally for this item (“2. Approval of the Amendment and Restatement of the Amended and Restated 2004 Equity Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under Amended and Restated 2004 Equity Incentive ”): 97,782,771 for, 3,668,240 against — passed, per its Form 8-K filed May 16, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the amendment and restatement of the Amended and Restated 2004 Equity Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under the Amended and Restated 2004 Equity Incentive Plan by an additional 5,000,000 shares of common stock and (ii) …”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 102 asset managers voting on “TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE CYTOKINETICS AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN T” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard16,589,7500 00For
Fidelity10,803,4230 00For
BlackRock8,890,3540 00For
T. Rowe Price6,814,0550 00For
State Street1,639,931103 00For
Charles Schwab1,301,1190 00For
Capital Group1,168,1100 00For
JPMorgan690,2880 00For
Columbia Threadneedle663,2810 00For
Jackson National606,6550 00For
Aberdeen602,4210 00For
Equitable556,9600 00For
AllianceBernstein462,4730 00For
Principal421,7130 00For
MUTUAL FUND SERIES TRUST382,0790 00For
HARBOR FUNDS360,8300 00For
Invesco315,6600 00For
Prudential/PGIM4,590308,154 00Against
Goldman Sachs309,1150 00For
Brown Advisory Funds294,6680 00For
TIAA287,3270 00For
American Century0283,535 00Against
MFS283,4950 00For
Hartford271,1350 00For
AB DISCOVERY GROWTH FUND, INC.266,7380 00For

Fund voting reports, all 102 managers: 57,693,977 for, 922,368 against, 34,323 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE CYTOKINETICS AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN T” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RP Management, LLC980,3920 00For
Erste Asset Management GmbH60,4500 00For
Maj Invest Holding A/S3,0450 00For

Institutional-manager reports, all 3 managers: 1,043,887 for.

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 14 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 96,760,272AGAINST: 4,607,831

Prior year: 96.7% for (May 15, 2024 meeting) ▼ 1.2 pts

Details: description as filed, official tally, votes by 350 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement.

CYTOKINETICS INC.’s own tally for this item (“5. Advisory Vote on Executive Compensation”): 96,760,272 for, 4,607,831 against — passed, per its Form 8-K filed May 16, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5: Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company's Proxy Statement for the 2025 Annual Meeting of Shareholders.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 102 asset managers voting on “To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, a” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard16,588,904846 00For
Fidelity10,803,4230 00For
BlackRock8,890,3540 00For
T. Rowe Price6,814,0550 00For
State Street1,640,0340 00For
Charles Schwab1,301,1190 00For
Capital Group1,168,1100 00For
JPMorgan690,2880 00For
Columbia Threadneedle663,2810 00For
Jackson National606,6550 00For
Aberdeen602,4210 00For
Equitable556,9600 00For
AllianceBernstein462,4730 00For
Principal421,7130 00For
MUTUAL FUND SERIES TRUST382,0790 00For
HARBOR FUNDS360,8300 00For
Invesco0315,660 00Against
Prudential/PGIM312,7440 00For
Goldman Sachs309,1150 00For
Brown Advisory Funds294,6680 00For
TIAA287,3270 00For
American Century0283,535 00Against
MFS0283,495 00Against
Hartford271,1350 00For
AB DISCOVERY GROWTH FUND, INC.266,7380 00For

Fund voting reports, all 102 managers: 57,587,126 for, 1,029,219 against, 34,323 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 274 asset managers voting on “To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, a” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price11,500,7020 00For
Fidelity9,264,5170 00For
Wellington7,006,5030 00For
State Street4,492,1430 00For
BlackRock4,433,3571,007 00For
GEODE CAPITAL MANAGEMENT, LLC2,775,8390 00For
PICTET ASSET MANAGEMENT SA1,644,0240 00For
ORBIMED ADVISORS LLC1,509,2050 00For
AllianceBernstein1,367,5130 00For
Vestal Point Capital, LP1,329,3520 00For
Charles Schwab1,324,1920 00For
Capital Group1,168,1190 00For
RP Management, LLC980,3920 00For
JPMorgan975,2560 00For
BROWN ADVISORY INC917,6660 00For
WESTFIELD CAPITAL MANAGEMENT CO LP857,5300 00For
Northern Trust763,1160 00For
Janus Henderson750,7540 00For
Fisher Asset Management, LLC711,8400 00For
RTW INVESTMENTS, LP705,6350 00For
MELLON INVESTMENTS Corp700,9310 00For
Point72697,9690 00For
JENNISON ASSOCIATES LLC606,6480 00For
Aberdeen602,4210 00For
Sarissa Capital Management LP0600,000 00Against

Institutional-manager reports, all 274 managers: 67,578,328 for, 3,728,224 against, 150,984 abstained, 7,185 not voted, 100,100 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year…

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 110,254,216AGAINST: 77,441

Prior year: 99.9% for (May 15, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Cytokinetics, Incorporated's independent registered public accounting firm for the fiscal year ending December 31, 2025.

CYTOKINETICS INC.’s own tally for this item (“4. Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025”): 110,254,216 for, 77,441 against — passed, per its Form 8-K filed May 16, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025 The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent reg…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 102 asset managers voting on “To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Cytokin” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard16,589,7500 00For
Fidelity10,803,4230 00For
BlackRock8,890,3540 00For
T. Rowe Price6,814,0550 00For
State Street1,640,0340 00For
Charles Schwab1,301,1190 00For
Capital Group1,168,1100 00For
JPMorgan690,2880 00For
Columbia Threadneedle663,2810 00For
Jackson National606,6550 00For
Aberdeen602,4210 00For
Equitable556,9600 00For
AllianceBernstein462,4730 00For
Principal421,7130 00For
MUTUAL FUND SERIES TRUST382,0790 00For
HARBOR FUNDS360,8300 00For
Invesco315,6600 00For
Prudential/PGIM312,7440 00For
Goldman Sachs309,1150 00For
Brown Advisory Funds294,6680 00For
TIAA287,3270 00For
American Century283,5350 00For
MFS283,4950 00For
Hartford271,1350 00For
AB DISCOVERY GROWTH FUND, INC.266,7380 00For

Fund voting reports, all 102 managers: 58,607,855 for, 8,490 against, 34,323 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 2 asset managers voting on “To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Cytokin” at CYTOKINETICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RP Management, LLC980,3920 00For
Erste Asset Management GmbH60,4500 00For

Institutional-manager reports, all 2 managers: 1,040,842 for.

Largest CYTOKINETICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 118,209,139 shares outstanding at the time of that meeting.

Fund voting reports: top CYTOKINETICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 14.03%
2Fidelity 9.14%
3BlackRock 7.52%
4T. Rowe Price 5.76%
5State Street 1.39%
6Charles Schwab 1.10%
7Capital Group 0.99%
8JPMorgan 0.58%
9Columbia Threadneedle 0.56%
10Jackson National 0.51%
Institutional-manager reports: top CYTOKINETICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named…”, 2024-2025
#Asset manager % of shares outstanding
1T. Rowe Price 9.73%
2Fidelity 7.84%
3Wellington 5.93%
4State Street 3.80%
5BlackRock 3.75%
6GEODE CAPITAL MANAGEMENT, LLC 2.35%
7PICTET ASSET MANAGEMENT SA 1.39%
8ORBIMED ADVISORS LLC 1.28%
9AllianceBernstein 1.16%
10Vestal Point Capital, LP 1.12%

Reported CYTOKINETICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

CYTOKINETICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock15,563,778 13.17%Form 13F, quarter ended March 31, 2025
Entities affiliated with BlackRock, Inc.15,252,905 12.90%Proxy statement (DEF 14A), proxy filed April 10, 2025
The Vanguard Group11,915,821 10.08%Proxy statement (DEF 14A), proxy filed April 10, 2025
Entities affiliated with Fidelity Investments11,146,954 9.43%Proxy statement (DEF 14A), proxy filed April 10, 2025
FMR (Fidelity)10,316,131 8.73%Form 13F, quarter ended March 31, 2025
Wellington Management7,988,740 6.76%Form 13F, quarter ended March 31, 2025
Entities affiliated with Wellington Management Group LLP6,530,884 5.52%Proxy statement (DEF 14A), proxy filed April 10, 2025
State Street6,085,001 5.15%Form 13F, quarter ended March 31, 2025
T. Rowe Price1,993,896 1.69%Form 13F, quarter ended March 31, 2025
Point721,722,984 1.46%Form 13F, quarter ended March 31, 2025

Percentages above are of 118,209,139 shares outstanding, as reported by CYTOKINETICS INC. on its Form 10-K dated December 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At CYTOKINETICS INC.'s shareholder meeting held May 14, 2025, in the 2024-2025 proxy season, 352 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 3,391 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named… — CYTOKINETICS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CYTOKINETICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 16, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CYTOKINETICS INC.’s 10-K dated December 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

CYTOKINETICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “CYTOKINETICS (CYTK) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cytokinetics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.